Teniposide

Summary

Teniposide (CHEMBL452231) is an approved small-molecule antineoplastic agent (ATC L01CB02) targeting TOP2A; indicated across 4 conditions including neoplasm and acute lymphoblastic leukemia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01CB02
• Targets: 1 (TOP2A)
• Indications: 4 conditions
• Clinical trials: 18
• Chemistry: 656.7 Da · C32H32O13S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL452231
Name	Teniposide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	452548
ChEBI	CHEBI:75988
ATC	L01CB02
Molecular formula	C32H32O13S
Molecular weight	656.7
InChIKey	NRUKOCRGYNPUPR-QBPJDGROSA-N

SMILES: COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@@H](C4=CC5=C(C=C24)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)CO[C@H](O7)C8=CC=CS8)O)O

IUPAC name: (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one

ChEBI definition: A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.

Pharmacological roles (ChEBI): antineoplastic agent, EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor.

Also known as: NSC-122819, Teniposide, Teniposido, VM-26, VM26, Vumon, teniposide, TENIPOSIDE, NA

Patent coverage: 33,166 distinct patent families (136,487 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 136,486 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
TOP2A	DNA topoisomerase II alpha	Inhibition		99.6% (common-essential)	P11388

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: ATP-binding cassette sub-family C member 4, DNA topoisomerase II, ATP-binding cassette sub-family C member 3.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TOP2A.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Transcription of E2F targets under negative control by DREAM complex	1	TOP2A
SUMOylation of DNA replication proteins	1	TOP2A

Dominant GO biological processes

GO term	Targets
resolution of meiotic recombination intermediates	1
sister chromatid segregation	1
hematopoietic progenitor cell differentiation	1
DNA topological change	1
chromatin organization	1
DNA damage response	1
chromosome segregation	1
female meiotic nuclear division	1
apoptotic chromosome condensation	1
embryonic cleavage	1
regulation of circadian rhythm	1
positive regulation of apoptotic process	1
positive regulation of single stranded viral RNA replication via double stranded DNA intermediate	1
positive regulation of transcription by RNA polymerase II	1
rhythmic process	1

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
acute lymphoblastic leukemia	3	MONDO:0004967	EFO:0000220
leukemia	2	MONDO:0005059	EFO:0000565
lymphoma	2	MONDO:0005062	EFO:0000574

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	7
PHASE4	6
Not specified	2
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00198991	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
NCT00199004	PHASE4	COMPLETED	Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
NCT00199056	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)
NCT00199069	PHASE4	COMPLETED	German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93)
NCT00199095	PHASE4	COMPLETED	Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia
NCT00853008	PHASE4	COMPLETED	Treatment of High Risk Adult Acute Lymphoblastic Leukemia
NCT07185373	PHASE2/PHASE3	NOT_YET_RECRUITING	Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT00187083	PHASE3	COMPLETED	A Study of Children With Refractory or Relapsed ALL
NCT06758700	PHASE2	RECRUITING	Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
NCT07188441	PHASE2	RECRUITING	Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
NCT07583511	PHASE2	RECRUITING	Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study
NCT00002531	PHASE2	UNKNOWN	Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
NCT00004231	PHASE2	COMPLETED	Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
NCT00004916	PHASE1/PHASE2	COMPLETED	Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin’s Lymphoma
NCT00186875	PHASE2	COMPLETED	Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT01700946	PHASE2	COMPLETED	Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
NCT00343369	Not specified	UNKNOWN	Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
NCT06048107	Not specified	UNKNOWN	Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

27 molecules share ≥1 primary target. Top 27 by shared-target count:

Molecule	Source	Status	Shared targets
AMSACRINE	ChEMBL	Phase 4 (approved)	TOP2A
CIPROFLOXACIN	ChEMBL	Phase 4 (approved)	TOP2A
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	TOP2A
DEXRAZOXANE	ChEMBL	Phase 4 (approved)	TOP2A
DOXORUBICIN	ChEMBL	Phase 4 (approved)	TOP2A
EPIRUBICIN	ChEMBL	Phase 4 (approved)	TOP2A
ETOPOSIDE	ChEMBL	Phase 4 (approved)	TOP2A
IDARUBICIN	ChEMBL	Phase 4 (approved)	TOP2A
MITOXANTRONE	ChEMBL	Phase 4 (approved)	TOP2A
TOPOTECAN	ChEMBL	Phase 4 (approved)	TOP2A
CURCUMIN	ChEMBL	Phase 3	TOP2A
GEPOTIDACIN	ChEMBL	Phase 3	TOP2A
AXL-1717	ChEMBL	Phase 2	TOP2A
DECERNOTINIB	ChEMBL	Phase 2	TOP2A
LOSOXANTRONE	ChEMBL	Phase 2	TOP2A
NEMORUBICIN	ChEMBL	Phase 2	TOP2A
PIROXANTRONE	ChEMBL	Phase 2	TOP2A
Afatinib	PubChem	Approved	TOP2A
Binimetinib	PubChem	Approved	TOP2A
Crizotinib	PubChem	Approved	TOP2A
Gefitinib	PubChem	Approved	TOP2A
Idelalisib	PubChem	Approved	TOP2A
Pazopanib	PubChem	Approved	TOP2A
podofilox	PubChem	Approved	TOP2A
regorafenib	PubChem	Approved	TOP2A
Selumetinib	PubChem	Approved	TOP2A
Trametinib	PubChem	Approved	TOP2A